# Zephyr AI

> Zephyr AI transforms real\-world data into actionable insights for drug discovery and diagnostics, delivering precision medicine solutions that scale\.

Generated by Yoast SEO v28.4, this is an llms.txt file, meant for consumption by LLMs.

## Pages
- [About Us](https://zephyrai.bio/about-us/)
- [News](https://zephyrai.bio/news/)
- [Contact](https://zephyrai.bio/contact/)
- [Resources](https://zephyrai.bio/resources/)
- [Platform](https://zephyrai.bio/platform/)

## Posts
- [Zephyr AI Names Lisa Eli Chief Scientific Officer to Expand Precision Oncology Strategy](https://zephyrai.bio/zephyr-ai-names-lisa-eli-chief-scientific-officer-to-expand-precision-oncology-strategy/)
- [Multimodal AI predicts immune checkpoint inhibitor response from clinically available inputs and whole\-slide images with explainable tumor biology and combination therapy insights](https://zephyrai.bio/multimodal-ai-predicts-immune-checkpoint-inhibitor-response-from-clinically-available-inputs-and-whole-slide-images-with-explainable-tumor-biology-and-combination-therapy-insights/): This research presents Zephyr AI’s AIM\-io model, a multimodal machine learning approach that predicts response to immune checkpoint inhibitors using routine clinical inputs, across 3 independent datasets: tissue\-derived data, liquid biopsy, and whole\-slide images\. Across multiple real\-world cohorts, AIM\-io improves prediction of survival outcomes compared to conventional biomarkers and identifies biologically meaningful tumor microenvironment features associated with response\. The model reconstructs immune programs and therapeutic vulnerabilities, enabling interpretable insights into mechanisms of sensitivity and resistance\. These capabilities support more precise patient stratification and rational design of combination immunotherapy strategies\.
- [Real world prediction and biological characterization of sotorasib sensitivity using multimodal AI and liquid biopsy genomic inputs](https://zephyrai.bio/real-world-prediction-and-biological-characterization-of-sotorasib-sensitivity-using-multimodal-ai-and-liquid-biopsy-genomic-inputs/): This study demonstrates Zephyr AI’s multimodal AIM\-Bx platform for predicting response to KRAS inhibitors in non\-small cell lung cancer using clinically available data, including ctDNA\. Applied to a real\-world cohort, the model identifies patients deriving meaningful benefit from sotorasib beyond KRAS mutation status alone\. AIM captures underlying tumor states and pathway dependencies associated with response heterogeneity, including MAPK reactivation and alternative signaling programs\. These findings highlight the value of functional, biology\-informed biomarkers for patient stratification and therapeutic decision\-making in KRAS\-driven cancers
- [Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights](https://zephyrai.bio/guardant-health-and-zephyr-ai-announce-partnership-to-unlock-drug-response-predictions-and-biomarker-insights/)

## Our Team
- [Allen Chao, PhD](https://zephyrai.bio/team-member/allen-chao-ph-d/)
- [Jeff Sherman, MSCS](https://zephyrai.bio/team-member/jeff-sherman-mscs/)
- [Lisa Eli, PhD](https://zephyrai.bio/team-member/lisa-eli-phd/)
- [Grant Verstandig](https://zephyrai.bio/team-member/grant-verstandig/)
- [John Applegate, MBA](https://zephyrai.bio/team-member/john-applegate-mba/)

## Categories
- [Media Coverage](https://zephyrai.bio/category/media-coverage/)
- [Press Releases](https://zephyrai.bio/category/press-releases/)
- [Resources](https://zephyrai.bio/category/resources/)

## Team Categories
- [Board of Directors](https://zephyrai.bio/team-category/board-of-directors/)
- [Leadership](https://zephyrai.bio/team-category/leadership/)
- [Scientific \& Medical Advisory Board](https://zephyrai.bio/team-category/scientific-medical-advisory-board/)
- [Advisors](https://zephyrai.bio/team-category/advisors/)

## Optional
- [Sitemap index](https://zephyrai.bio/sitemap_index.xml)